Haemonetics Corporation (NYSE:HAE) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Haemonetics Corporation (NYSE:HAE) have been assigned a consensus rating of “Moderate Buy” from the eleven research firms that are currently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, three have given a hold recommendation, six have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $78.3333.

Several analysts have recently issued reports on the stock. Robert W. Baird set a $67.00 price target on shares of Haemonetics in a research report on Friday, May 8th. Barrington Research lowered their price target on shares of Haemonetics from $94.00 to $89.00 and set an “outperform” rating on the stock in a research report on Tuesday, May 12th. BTIG Research reissued a “buy” rating and issued a $84.00 price target on shares of Haemonetics in a research report on Wednesday, June 17th. JPMorgan Chase & Co. lowered their price target on shares of Haemonetics from $74.00 to $62.00 and set a “neutral” rating on the stock in a research report on Friday, May 8th. Finally, Mizuho boosted their price target on shares of Haemonetics from $70.00 to $85.00 and gave the company an “outperform” rating in a research report on Monday, June 15th.

Haemonetics Stock Performance

Shares of HAE stock opened at $72.95 on Wednesday. The firm has a market cap of $3.32 billion, a price-to-earnings ratio of 36.11, a P/E/G ratio of 1.46 and a beta of 0.56. The company has a debt-to-equity ratio of 1.53, a quick ratio of 1.87 and a current ratio of 2.95. Haemonetics has a 52 week low of $47.31 and a 52 week high of $87.32. The firm’s 50-day simple moving average is $64.49 and its two-hundred day simple moving average is $66.93.

Haemonetics (NYSE:HAE) last announced its quarterly earnings data on Thursday, May 7th. The medical instruments supplier reported $1.29 EPS for the quarter, topping the consensus estimate of $1.28 by $0.01. The business had revenue of $346.35 million for the quarter, compared to analyst estimates of $336.83 million. Haemonetics had a net margin of 7.29% and a return on equity of 27.30%. The company’s revenue for the quarter was up 4.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.24 earnings per share. Haemonetics has set its FY 2027 guidance at 5.258-5.307 EPS. As a group, equities analysts forecast that Haemonetics will post 5.22 earnings per share for the current year.

Institutional Trading of Haemonetics

Hedge funds and other institutional investors have recently modified their holdings of the business. Kemnay Advisory Services Inc. bought a new stake in shares of Haemonetics in the fourth quarter valued at approximately $26,000. True Wealth Design LLC raised its position in shares of Haemonetics by 6,700.0% in the fourth quarter. True Wealth Design LLC now owns 340 shares of the medical instruments supplier’s stock valued at $27,000 after purchasing an additional 335 shares during the period. Leonteq Securities AG bought a new stake in shares of Haemonetics in the fourth quarter valued at approximately $30,000. EverSource Wealth Advisors LLC grew its stake in Haemonetics by 2,640.0% during the second quarter. EverSource Wealth Advisors LLC now owns 411 shares of the medical instruments supplier’s stock valued at $31,000 after acquiring an additional 396 shares in the last quarter. Finally, Kestra Advisory Services LLC purchased a new position in Haemonetics during the fourth quarter valued at approximately $34,000. Institutional investors own 99.67% of the company’s stock.

About Haemonetics

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.